Advertisement

Im Focus Onkologie

, Volume 21, Issue 4, pp 34–37 | Cite as

Schwerwiegende Komplikationen vermeiden

Antimykotische Prophylaxe bei hämatologischen Patienten

  • Gerlinde Egerer
Supportivtherapie Fortbildung

Nach wie vor sind Patienten, die sich einer Stammzelltransplantation unterziehen, dem Risiko einer Pilzinfektion ausgesetzt, beispielsweise mit Candida albicans. Eine entsprechende Prophylaxe sollte daher Standard sein. Immer häufiger spielen auch Infektionen mit Aspergillus- und Mucorales-Spezies eine Rolle.

Literatur

  1. 1.
    Vehreschild JJ et al. Clinical effectiveness of Posaconazole prophylaxis in patients with acute myelogenous leukemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466–71.CrossRefGoogle Scholar
  2. 2.
    Slavin MA et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J. 2008;38(6b):468–76.CrossRefGoogle Scholar
  3. 3.
    Goodman JL et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.CrossRefGoogle Scholar
  4. 4.
    Rotstein C et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28(2):331–40.CrossRefGoogle Scholar
  5. 5.
    Cornely OA et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94(1):113–22.CrossRefGoogle Scholar
  6. 6.
    Maertens J et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update. Bone Marrow Transplant. 2011;46(5):709–18.CrossRefGoogle Scholar
  7. 7.
    Slavin MA et al. Efficacy and safety of fluconazole prophylaxis for gunal infections after marrow transplantation — a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.CrossRefGoogle Scholar
  8. 8.
    Glasmacher A et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother. 2006;57(2):317–25.CrossRefGoogle Scholar
  9. 9.
    Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348–59.CrossRefGoogle Scholar
  10. 10.
    Ullman AJ et al. Posaconazole or Fluconazole for Prophylaxis in severe graft-versus-hostdisease. N Engl J Med. 2007;356(4):335–47.CrossRefGoogle Scholar
  11. 11.
    Wingard JR et al. Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010; 116(24):5111–8.CrossRefGoogle Scholar
  12. 12.
    Van Burik JA et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.CrossRefGoogle Scholar
  13. 13.
    Hashino S et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol. 2008;87(1):91–7.CrossRefGoogle Scholar
  14. 14.
    Nihtinen A et al. Low incindence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transpl Infect Dis. 2012;14(1):24–32.CrossRefGoogle Scholar
  15. 15.
    El-Cheikh J et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(5):301–6.CrossRefGoogle Scholar
  16. 16.
    Peterson L et al. Posaconazole prophylaxis—impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses. 2013;56(6):651–8.CrossRefGoogle Scholar
  17. 17.
    Kraft WK et al. Posaconazole tablet pharmacokinetics: Lack of effect on concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrobial Agents Chemother. 2014;58(7):4020–5.CrossRefGoogle Scholar
  18. 18.
    Pham AN et al. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses. 2016;59(4):226–33.CrossRefGoogle Scholar
  19. 19.
    Maertens JA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus or other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.CrossRefGoogle Scholar
  20. 20.
    Gebremariam T et al. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrob Agents Chemother. 2017;61(5):e02589–16.CrossRefGoogle Scholar
  21. 21.
    Cornely OA et al. Safety and pharmacokinetics of Isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrobial Agents Chemother. 2015;59(4):2078–85.CrossRefGoogle Scholar
  22. 22.
    Cornely OA et al. AmBiGuard Study Group. Randomized comparison of liposomales Amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblasic leukemia. J Antimicrobial Chemother. 2017;72(8):2359–67.CrossRefGoogle Scholar
  23. 23.
    Mattiuzzi GN et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143–7.CrossRefGoogle Scholar
  24. 24.
    Cordonnier C et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.CrossRefGoogle Scholar
  25. 25.
    Cornet M et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20(7): 508–13.CrossRefGoogle Scholar
  26. 26.
    Moriyama B et al. Adverse Interactions between antifungal Azolen and vincristine: Review and analysis of cases. Mycoses. 2012;55(4):290–7.CrossRefGoogle Scholar
  27. 27.
    Trifilio S et al. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant. 2004;33(7):735–9.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik V — Hämatologie, Onkologie u. RheumatologieUniversitätsklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations